Sectors

KPRX
Kiora Pharmaceuticals, Inc.
2.51
2 x 1.93
2 x 3.46
bid
ask
-
0.11
4.20%
2 @ 04:10 PM
2.51 +0.00 (0.00%)
Ytd27.41%
1y-9.71%
2.51
day range
2.56
1.76
52 week range
2.95
Open2.52Prev Close2.62Low2.51High2.56Mkt Cap11.11M
Vol14.10KAvg Vol21.40KEPS-2.32P/EN/AForward P/E-1.48
Beta-0.29Short Ratio0.27Inst. Own48.34%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1150-d Avg2.57200-d Avg2.321yr Est40.50

KPRX News

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
newsfilecorp.com
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPR

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
newsfilecorp.com
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPR

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
newsfilecorp.com
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

benzinga.com
Kiora Pharmaceuticals Released Preclinical Data Showing That KIO-300 Significantly Suppressed Seizur

Kiora Pharmaceuticals (NASDAQ:KPRX) today announced preclinical data showing that KIO-300, part of t

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
newsfilecorp.com
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Pre

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epil

benzinga.com
Kiora Pharmaceuticals Files Prospectus For Offering 11.797M Common Stock On Behalf Of Selling Shareh

https://www.sec.gov/Archives/edgar/data/1372514/000137251426000050/s-3xapril2026.htm

benzinga.com
Kiora Pharmaceuticals Q1 EPS $(0.58) Beats $(0.71) Estimate

Kiora Pharmaceuticals (NASDAQ:KPRX) reported quarterly losses of $(0.58) per share which beat the an

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
newsfilecorp.com
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today r

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
newsfilecorp.com
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) toda

Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)
defenseworld.net
Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)

Cronos Group (NASDAQ: CRON - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Rep

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Kiora Pharmaceuticals Announces Management Team Changes
newsfilecorp.com
Kiora Pharmaceuticals Announces Management Team Changes

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

benzinga.com
Kiora Pharmaceuticals Q4 EPS $(1.60) Misses $(0.67) Estimate

Kiora Pharmaceuticals (NASDAQ:KPRX) reported quarterly losses of $(1.60) per share which missed the

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
newsfilecorp.com
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Di

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
newsfilecorp.com
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: K

Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)
defenseworld.net
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)

Stevanato Group (NYSE: STVN - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Re

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
newsfilecorp.com
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) ha

benzinga.com
Kiora Pharmaceuticals Secures New US Patent to Expand Delivery Options for Eye Drug KIO-104

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) today announced that the U.S. Patent and Trademark Office

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
newsfilecorp.com
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For November 7, 2025
benzinga.com
Earnings Scheduled For November 7, 2025

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
newsfilecorp.com
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Activel

Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

benzinga.com
Kiora Pharmaceuticals Joins Global Genes' RARE-X Vision Consortium, A Corporate-Nonprofit Initiative

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Glo

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
prnewswire.com
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New

ENCINITAS, Calif. and WASHINGTON D.C.

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
newsfilecorp.com
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

Kiora (KPRX) Q2 Revenue Falls 100%
fool.com
Kiora (KPRX) Q2 Revenue Falls 100%

Kiora (KPRX) Q2 Revenue Falls 100%

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
newsfilecorp.com
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active

Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day

Shares of Skechers U.S.A., Inc. (NYSE: SKX) shares fell during Friday’s session after the company r

benzinga.com
Why Meta Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Shares of Meta Platforms, Inc. (NASDAQ: META) rose sharply in today’s pre-market trading as the comp

benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's M

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after

benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session

benzinga.com
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Shares of Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the co

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 164 companies achieved new lows for the year.

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 128 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 155 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 54 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 35 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 29 companies set new 52-week lows.